145 related articles for article (PubMed ID: 37959801)
1. LCK-SafeScreen-Model: An Advanced Ensemble Machine Learning Approach for Estimating the Binding Affinity between Compounds and LCK Target.
Cheng Y; Ji C; Xu J; Chen R; Guo Y; Bian Q; Shen Z; Zhang B
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959801
[TBL] [Abstract][Full Text] [Related]
2. Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.
Huang N; Nagarsekar A; Xia G; Hayashi J; MacKerell AD
J Med Chem; 2004 Jul; 47(14):3502-11. PubMed ID: 15214778
[TBL] [Abstract][Full Text] [Related]
3. Discovering the Active Ingredients of Medicine and Food Homologous Substances for Inhibiting the Cyclooxygenase-2 Metabolic Pathway by Machine Learning Algorithms.
Tian Y; Zhang Z; Yan A
Molecules; 2023 Sep; 28(19):. PubMed ID: 37836625
[TBL] [Abstract][Full Text] [Related]
4. SVM model for virtual screening of Lck inhibitors.
Liew CY; Ma XH; Liu X; Yap CW
J Chem Inf Model; 2009 Apr; 49(4):877-85. PubMed ID: 19267483
[TBL] [Abstract][Full Text] [Related]
5. New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (Lck) inhibitors: a decade review (2011-2021) focussing on structure-activity relationship (SAR) and docking insights.
Elkamhawy A; Ali EMH; Lee K
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1574-1602. PubMed ID: 34233563
[TBL] [Abstract][Full Text] [Related]
6. P56(lck) kinase inhibitor studies: a 3D QSAR approach towards designing new drugs from flavonoid derivatives.
Gunda SK; Narasimha SK; Shaik M
Int J Comput Biol Drug Des; 2014; 7(2-3):278-94. PubMed ID: 24878734
[TBL] [Abstract][Full Text] [Related]
7. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.
Zhu X; Kim JL; Newcomb JR; Rose PE; Stover DR; Toledo LM; Zhao H; Morgenstern KA
Structure; 1999 Jun; 7(6):651-61. PubMed ID: 10404594
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of p56(lck) tyrosine kinase by isothiazolones.
Trevillyan JM; Chiou XG; Ballaron SJ; Tang QM; Buko A; Sheets MP; Smith ML; Putman CB; Wiedeman P; Tu N; Madar D; Smith HT; Gubbins EJ; Warrior UP; Chen YW; Mollison KW; Faltynek CR; Djurić SW
Arch Biochem Biophys; 1999 Apr; 364(1):19-29. PubMed ID: 10087161
[TBL] [Abstract][Full Text] [Related]
9. Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.
Farag AK; Elkamhawy A; Londhe AM; Lee KT; Pae AN; Roh EJ
Eur J Med Chem; 2017 Dec; 141():657-675. PubMed ID: 29107425
[TBL] [Abstract][Full Text] [Related]
10. Lead validation and SAR development via chemical similarity searching; application to compounds targeting the pY+3 site of the SH2 domain of p56lck.
Macias AT; Mia MY; Xia G; Hayashi J; MacKerell AD
J Chem Inf Model; 2005; 45(6):1759-66. PubMed ID: 16309282
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine phosphorylation-dependent activation of NF-kappa B. Requirement for p56 LCK and ZAP-70 protein tyrosine kinases.
Livolsi A; Busuttil V; Imbert V; Abraham RT; Peyron JF
Eur J Biochem; 2001 Mar; 268(5):1508-15. PubMed ID: 11231305
[TBL] [Abstract][Full Text] [Related]
12. TCR-induced T cell activation leads to simultaneous phosphorylation at Y505 and Y394 of p56(lck) residues.
Nyakeriga AM; Garg H; Joshi A
Cytometry A; 2012 Sep; 81(9):797-805. PubMed ID: 22674786
[TBL] [Abstract][Full Text] [Related]
13. Ensemble learning from ensemble docking: revisiting the optimum ensemble size problem.
Mohammadi S; Narimani Z; Ashouri M; Firouzi R; Karimi-Jafari MH
Sci Rep; 2022 Jan; 12(1):410. PubMed ID: 35013496
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of small chemical inhibitors containing different scaffolds for lck SH2 domain.
Park SH; Kang SH; Lim SH; Oh HS; Lee KH
Bioorg Med Chem Lett; 2003 Oct; 13(20):3455-9. PubMed ID: 14505648
[TBL] [Abstract][Full Text] [Related]
15. Modular folding and evidence for phosphorylation-induced stabilization of an hsp90-dependent kinase.
Hartson SD; Ottinger EA; Huang W; Barany G; Burn P; Matts RL
J Biol Chem; 1998 Apr; 273(14):8475-82. PubMed ID: 9525961
[TBL] [Abstract][Full Text] [Related]
16. Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck).
Wityak J; Das J; Moquin RV; Shen Z; Lin J; Chen P; Doweyko AM; Pitt S; Pang S; Shen DR; Fang Q; de Fex HF; Schieven GL; Kanner SB; Barrish JC
Bioorg Med Chem Lett; 2003 Nov; 13(22):4007-10. PubMed ID: 14592495
[TBL] [Abstract][Full Text] [Related]
17. Insights into human Lck SH3 domain binding specificity: different binding modes of artificial and native ligands.
Tran T; Hoffmann S; Wiesehan K; Jonas E; Luge C; Aladag A; Willbold D
Biochemistry; 2005 Nov; 44(45):15042-52. PubMed ID: 16274251
[TBL] [Abstract][Full Text] [Related]
18. SH2-directed ligands of the Lck tyrosine kinase.
Lee TR; Lawrence DS
J Med Chem; 2000 Mar; 43(6):1173-9. PubMed ID: 10737750
[TBL] [Abstract][Full Text] [Related]
19. Molecular docking guided 3D-QSAR CoMFA analysis of N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of leukocyte-specific protein tyrosine kinase.
Awale M; Mohan CG
J Mol Model; 2008 Oct; 14(10):937-47. PubMed ID: 18626671
[TBL] [Abstract][Full Text] [Related]
20. Genetically encoded Förster resonance energy transfer sensors for the conformation of the Src family kinase Lck.
Paster W; Paar C; Eckerstorfer P; Jakober A; Drbal K; Schütz GJ; Sonnleitner A; Stockinger H
J Immunol; 2009 Feb; 182(4):2160-7. PubMed ID: 19201869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
